Actinogen Medical Limited · ASX:ACW

Actinogen Medical — ShareCafe Small Cap "Hidden Gems" Webinar 2021

16 slides from Actinogen Medical's conference presentation, Aug 6, 2021

  1. Slide 1: Actinogen to present at ShareCafe Small Cap Webinar

    ASX ANNOUNCEMENT Actinogen to present at ShareCafe Small Cap Webinar Sydney, 4 August 2021. Actinogen Medical ASX: ACW (‘Actinogen’ or ‘the Company’) is pleased to announce its participation in the ShareCafe Small Cap "Hidden Gems" Webinar, to be held Friday 6th of August 2021 from 12:30pm AEST / 10

  2. Slide 2: Disclaimer

    In the Company’s recent XanaHES Phase I trial, Xanamem exhibited a statistically significant improvement in cognition among healthy older volunteers, and recent human target engagement data for the drug in the brain suggests good activity of doses as low as 5mg daily. The Company plans to initiate a

  3. Slide 3: ShareCafe Presentation

    ShareCafe Presentation Dr. Steven Gourlay: CEO & Managing Director 6 August 2021

  4. Slide 4: Disclaimer

    Disclaimer This presentation has been prepared by Actinogen Medical Limited. (“Actinogen” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to mak

  5. Slide 5: Actinogen snapshot

    Actinogen snapshot Actinogen Medical (ASX:ACW) is a public company developing Xanamem®; a novel small molecule for cognitive impairment Favourable drug Substantial Clinical Data Attractive targets Protected & Funded  Brain penetrant, 11β-  >200 subjects treated  Significant opportunity in  Compr

  6. Slide 6: Corporate overview

    Corporate overview Major shareholders remain supportive through share price appreciation Major Shareholders Experienced Board & Senior Management BVF Partners 14.4% Steven Gourlay1 3.8% Edinburgh Technology Fund 2.9% BVF Partners Dr. Geoff Dr. George Mr. Malcolm Dr. Steven Jeff Carter Tamara Miller

  7. Slide 7: Xanamem – small molecule drug with a novel mechanism of action

    Xanamem – small molecule drug with a novel mechanism of action Xanamem is a brain1 penetrant 11β-HSD1 small molecule enzyme inhibitor; designed to inhibit excessive cortisol production in the brain 1. Xanamem is a CNS (Central Nervous System) penetrant small molecule 5

  8. Slide 8: Clinical pipeline for Xanamem

    Clinical pipeline for Xanamem Major clinical trials targeting brain penetration, improved cognition and other benefits Planned studies Pathway (illustrative) Outlook Mild cognitive XanaMIA - Commenced Potential to address impairment due to Part A: 10mg, 5mg, Placebo all stages of the Part B: MCI due

  9. Slide 9: Breakthrough results achieved in Phase 1 study

    Breakthrough results achieved in Phase 1 study Phase 1 XanaHES study demonstrated statistically significant cognitive efficacy signal in multiple cognition domains based on Cogstate Cognitive Test Battery as early as 2 weeks1 Working memory (One Back Test) Visual attention (Identification Test) Psyc

  10. Slide 10: Bridging the positive Phase 1 cognition data to Alzheimer's patients

    Bridging the positive Phase 1 cognition data to Alzheimer’s patients Targeting the first stage of Alzheimer’s disease, measuring biomarkers XanaMIA XanaMIA Part A Part B Functional Impairment in later AD Target market Healthy older patients Mild Mild Cognitive Clinical AD Moderate Severe Impairment

  11. Slide 11: XanaMIA Phase II trial has commenced

    XanaMIA Phase II trial has commenced XanaMIA trial design is optimised for success XanaMIA - Part A XanaMIA - Part B (expected results in 1H CY22) (expected results in CY23)  Healthy older subjects - with normal cognition,  Targeting subjects with mild cognitive impairment ≥50 years of age (same a

  12. Slide 12: Review of data supports a low Xanamem dose

    Review of data supports a low Xanamem dose Human Target Occupancy Study PET data demonstrates consistent suppression of enzyme activity at 5mg Xanamem doses and above BASELINE AFTER DOSE 5mg Xanamem 10mg Xanamem 20mg Xanamem SUVRcarotid PET data demonstrates that Xanamem extensively binds to the 11β

  13. Slide 13: Fragile X Phase II trial to commence in 2H CY21

    Fragile X Phase II trial to commence in 2H CY21 Anxiety, sleep and behavioural problems in Fragile X syndrome are often associated with raised cortisol; Xanamem has the potential to improve symptoms  Rare genetic condition, with life-long treatment required for patients (management is often Unmet M

  14. Slide 14: Significant value upside for Actinogen

    Significant value upside for Actinogen Accelerate clinical development Potential commercial value Expand pipeline to show efficacy Big Pharma Partnership(s)  Expand pipeline with additional indications and clinical  Actively engaging with potential future partners trials, providing multiple shots

  15. Slide 15: Esteemed Advisory Boards

    Esteemed Advisory Boards World-leading, premier academics involved in the development of Xanamem Xanamem Clinical Advisory Board Scientific Advisory Board Positions Xanamem at the forefront Combining deep understanding of endocrinology, of drug development 11β-HSD1 and drug discovery Prof. Craig Rit

  16. Slide 16: Next steps and key catalysts

    Next steps and key catalysts Actinogen has a strong balance sheet to execute its strategy and progress Xanamem clinical development  Clinical trials to commence in 2021*  XanaMIA Part A data expected in 1H2022  XanaFX data expected 2023  XanaMIA Part B data expected 2023  Pursue other high prio

Actinogen Medical — ShareCafe Small Cap "Hidden Gems" Webinar 2021 on 6ix